Debt Collection Reports
11th October 2021
The International Debt Collections Handbook is a key tool for businesses when it comes to making decisions concerning collections in foreign countries.
Stay on top of your business’ cash flow by gearing up with insightful content. Find reports, guides and business insights from our experts on how to successfully manage B2B collection.
Access a snapshot of the credit risk situation and business performance of 14 major industries in your country. The forecast is based on the assessment of Atradius underwriters.
Showing 101-150 of 913 items
Payment Practices Barometer
28th June 2022
A wide range of protective measures to mitigate against the impact of customer payment default were used by businesses polled in the United Arab Emirates.
Our survey shows a sharp rise in bad debts written off as uncollectable, revealing a disturbing deterioration in B2B payment practices.
An alarming increase in bad debt write-offs worries companies in Hong Kong, prompting them to seek strategic credit risk management solutions.
Companies polled in India told us of the difficulty they found in collecting long unpaid trade debt.
16th June 2022
ICT is expected to be among the fastest growing sectors in manufacturing, driven by accelerating digitalisation and industrial automation
Lower, but still solid ICT sales and production growth
Government aims to accelerate the digital transformation
Main issues are chip shortage and inflationary pressures
Ongoing domestic sales growth, but there are downside risks
Solid ICT growth expected during the coming years
Digital transformation is a major growth driver
Robust growth continues due to high demand for chips
Smaller ICT retailers face more problems in the coming months
Profit margins of ICT businesses should increase again in 2022
ICT Sales growth maintained by businesses and public bodies
Slowdown in demand, and higher input prices
Solid performance, but high input prices could become an issue
25th May 2022
Energy Outlook based on the IEA's World Energy Outlook
24th May 2022
The Covid-19 pandemic and the Russia-Ukraine war pose challenges to global value chains.
18th May 2022
High levels of unpaid debt prompt stronger credit controls among Australian businesses as they battle it out for survival in a competitive market.
17th May 2022
Ongoing, but lower sales growth in 2022
Rising insolvencies as fiscal support expired
Lockdowns and a slowdown in the property sector affect demand
Higher input costs and supply chain issues hit profit margins
A more difficult year ahead
More brick-and-mortar retailers will leave the market
More difficult market conditions after robust growth in 2021
More insolvencies expected in 2022
High inflation and lower consumer confidence weigh on sales
Profit margins should remain stable, but downside risks remain
Retailers´ profit margins sustained by fiscal support
Decreasing profit margins for brick-and-mortar retailers
3rd May 2022
Reviving Latin America's energy transition requires wind and solar
12th April 2022
Russia's invasion of Ukraine throws sand in the wheels of the global economy.
As government support after the pandemic is phased out, insolvencies in most markets are projected to increase in 2022 and 2023.
24th March 2022
Chinese economic growth slows down amid several downside risks
15th March 2022
Covid-19 vaccine production and aging populations drive growth for pharmaceuticals industry
Robust growth expected in 2022
A vast market with growing sales opportunities
Robust output growth expected in 2022
Large backlog of medical treatments to sustain growth in the coming years
Healthy profit margins despite public pressure to lower sales prices
Growing share of generics could affect local producers
Increase in production of primary products planned to lower reliance on China
High days sales outstanding in the wholesalers segment
A major drug production hub with good growth prospects
Business margins expected to increase again in 2022
Stable profit margins despite inflationary pressures
Good growth prospects, but also constraints due to lower public healthcare spend
Sharp output growth in 2021 due to vaccine production